CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGNEDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping
CONNECT1 – EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping
